Sunday, August 29, 8:15 - 9:20 a.m. - Waterfront III

Esophageal stem cells and 3D cell culture models

H. Mashimo (Boston)

     


Sunday, August 29, 10:55 a.m. -12:00 p.m. - Waterfront III

Barrett's esophagus and regenerative medicine

S. Badylak (Pittsburgh) - B.A. Jobe (Pittsburgh)

     


Sunday, August 29, 2:30 - 3:35 p.m - Waterfront III

Cellular response to Acid and Bile

Chairs: H.S. Garewal (Tucson) - R.F. Souza (Dallas)

Introduction and overview. H.S. Garewal (Tucson)

Role of NADPH oxidase NOX5-S in acid induced progression from Barrett's esophagus to esophageal adenocarcinoma. W. Cao (Providence)

Role of acid and nitric oxide (NO) in the progression of Barrett's esophagus to esophageal adenocarcinoma. R.C. Fitzgerald (Cambridge, UK)

Role of bile acids and nitric oxide (NO) in the progression of Barrett's esophagus to esophageal adenocarcinoma. G.J. Jenkins (Swansea)

Bile acids cause DNA damage in benign Barrett's epithelial cells, which resist apoptosis through NF-kB activation. R.F. Souza (Dallas)

     


Sunday, August 29, 5:40 - 6:45 p.m. - Waterfront III

The esophago-gastric junction

Chairs: L.S. Miller (Philadelphia) - J.G. Brasseur (University Park)

The structure of the sphincteric segment between the stomach and esophagus. L.S. Miller (Philadelphia)

Defects within the sphincteric segment between the stomach and esophagus potentially leading to GERD: clinical studies. A.K. Vegesna

Defects within the gastro-esophageal sphincteric segment potentially leading to GERD: in-vitro muscle strip studies. M.R. Ruggeri (Philadelphia)

The protective mechanism of the sphincteric segment between the stomach and esophagus from a biomechanical perspective. J.G. Brasseur (University Park). 

     


Monday, August 30, 8:15 - 9:20 a.m. - Waterfront III

PPI’s in Barrett’s  - Everyone? Just some?
Effects of PPI’s in BE and requirements to normalize intra-esophageal pH

Chairs: R.K.H. Wong (Washington) - P.O. Katz (Philadelphia)

Effectiveness of PPI therapy in normalizing intraesophageal pH in patients with GERD and Barrett’s esophagus. P.O. Katz (Philadelphia)

Should the dose of PPI be the same for short vs. long segment Barrett’s Esophagus? J. Watson (Washington)
Should the esophageal refluxate be normalized in Barrett’s Esophagus?  In vitro studies to answer this question. G. Triadafilopoulos (Stanford)
Does PPI therapy affect mucosal biomarkers in Barrett’s epithelium? R.C. Fitzgerald (Cambridge)

Effects of long-term acid inhibition on gastrointestinal hormones and Barrett’s epithelium. P. Lao-Sirieix (Cambridge)

     


Monday, August 30, 10:55 p.m. - 12:00 p.m. - Waterfront III

The new requirements of endoscopy

Chairs: R. Shaker (Milwaukee) - I. F. Herrmann (Rome)

Developments towards High-Tech-Endoscopy

The Endoscopy of the Integrated Channel System
The risk of Infection
The disposable tube system – The technology
The disposable system in gastroenterology
Live demonstration of new disposable technology

     


Monday, August 30, 2:20 - 3:35 p.m. - Waterfront III

Cryotherapy in Barrett's esophagus

Chairs: N.J. Shaheen (Chapel Hill) - S.J. Sontag (Chicago)

Is cryotherapy a viable strategy for non-nodular low-grade and high-grade dysplasia in BE?
How does it stand in relation to other options for ablation? J. Dumot  (Cleveland)

What is the role of cryotherapy in esophageal adenocarcinoma? 
Is it a curative, or just palliative therapy? B.D. Greenwald (Baltimore)

Have dosimetry issues with cryotherapy been resolved?
If so, what is the appropriate dosing for Barrett’s? For Cancer? J. A. Abrams (New York)
What are the main toxicity issues with cryotherapy, and at what rate do they occur? M. H. Johnston (Lancaster)
What is the difference between Liquid Nitrogen and Carbon Dioxide cryotherapy systems with respect to efficacy?  With respect to side effects? C.J. Lightdale (New York)

     


Monday, August 30, 4:25 - 5:30 p.m. - Waterfront III

Mechanism-based evaluation & treatment of esophageal disorders

Chairs: H. Gregersen (Aalborg) - A.M. Drewes (Aalborg)

New technologies for individualized diagnosis of esophageal diseases. H. Gregersen (Aalborg)
Neurophysiological assessment of sensory abnormalities. J. Frokjaer (Aalborg)
Autonomous assessment of sensory abnormalities. Q. Aziz (London)
Mechanism-based treatment of esophageal disorders. M. Simren (Göteborg)

Clinical utility of using novel diagnostic combinations to guide mechanistically targeted esophageal therapeutic. A. Hobson (London)

     


Tuesday, August 31, 8:15 - 9:20 a.m. - Waterfront III

Esophageal problems in childhood: Neonate to Adolescent

Chairs: S.R. Jadcherla (Columbus) - B. Martin-Harris (Charleston)

Development of esophageal functions in infants S. R. Jadcherla (Columbus)

The physiologic swallow continuum: infants and young children M. Lepton-Greif (Baltimore)
The physiologic swallow continuum: older children and young adults B. Martin-Harris (Charleston)
Pediatric esophageal conditions with a potential risk for esophageal cancer S. Nurko (Boston)

     


Tuesday, August 31, 2:30 - 3:35 p.m - Waterfront III

Barrett's Registries

Chairs: C.P. Caygill (London) - P.A. Gatenby (London)

Do Barrett’s Registries have a role to play in research? P.A. Gatenby (London)
What dataset should be included? L.Murray (Belfast)

Do Registries have a role in the determination of pathological grading and can pathological progression (to dysplasia/invasive neoplasia) and regression be defined? M. Rugge (Padova)

How can Registry data be used to determine optimal surveillance interval to detect progression (six months, a year, two consecutive endoscopic check-ups)? G. Zaninotto (Padova)

What are the demographic, lifestyle and diagnostic differences between the USA and Europe and can these be overcome for future collaborative studies? Y. Romero (Rochester, MN)